Historic FDA Win: Pembrolizumab + EV Becomes New Standard for Cisplatin-Ineligible MIBC
Rishabh Jain, Medical Oncologist at AIIMS Delhi, posted on X:
”FDA APPROVAL – MIBC
Pembrolizumab + Enfortumab Vedotin gets approved as neoadjuvant → adjuvant therapy for cisplatin-ineligible muscle-invasive bladder cancer (MIBC)
Why this matters?
For the first time ever, a chemo-free neoadjuvant regimen improves BOTH EFS and OS in MIBC patients who cannot take cisplatin.
This is a new standard for a previously undertreated group.
KEYNOTE-905 / EV-303
Design:
Neoadjuvant Pembrolizumab + EV → cystectomy → adjuvant EV + Pembrolizumab → Pembrolizumab alone
vs
Immediate cystectomy alone
Population: Cisplatin-ineligible or cisplatin-declining MIBC patients.
Efficacy Highlights
EFS:
• Not reached vs 15.7 months
• HR 0.40 (60% risk reduction)
OS:
• Not reached vs 41.7 months
• HR 0.50 (50% risk reduction)
These are huge survival deltas for localized bladder cancer.
Regimen
Neoadjuvant (9 weeks):
• Pembrolizumab 200 mg Q3W
• EV 1.25 mg/kg D1 & D8 (Q3W) × 3 cycles
Adjuvant:
• EV × 6 cycles + Pembrolizumab (Q3W ×14 or Q6W ×7)
• Then Pembrolizumab alone → Total adjuvant duration 42 weeks
Safety Snapshot
Similar to prior EV + Pembro experience:
• Skin reactions
• Hyperglycemia
• ILD/pneumonitis
• Peripheral neuropathy
• Immune-related AEs from pembrolizumab
Takeaway
A practice-changing, chemo-free perioperative IO-ADC strategy for MIBC.
This is likely to shift guidelines fast – especially for cisplatin-ineligible patients.
Source: FDA (2025)”
Stay updated with Hemostasis Today.
-
Mar 13, 2026, 15:47Heghine Khachatryan: Real-World Data on DOAC Use in Pediatric Oncology
-
Mar 13, 2026, 15:29Megan Adediran: Heavy Period as a Sign of a Underlying Bleeding Disorder
-
Mar 13, 2026, 15:28Gareth Owens: Preventing Aortic Dissection Through Post-Mortem Genetics Testing
-
Mar 13, 2026, 14:20Tareq Abadl: How One Blood Donation Saves Three Lives
-
Mar 13, 2026, 14:10Julie Cardoso: Bringing Clinicians Together to Improve VTE Detection and Treatment
-
Mar 13, 2026, 13:10Hisam Siddiqi: Is FFP Really The Magic Elixir of All Coagulopathies in Liver Disease
-
Mar 13, 2026, 13:08Lena Volland: Screening Gaps and Clinical Outcomes of Iron Deficiency Anemia in Pregnancy
-
Mar 13, 2026, 13:05Sebastian Szmit: Managing Venous Thromboembolism and Anticoagulation in Cancer Patients
-
Mar 13, 2026, 12:43Annie Bauzon: HbA1c Insights and Clinical Importance in Diabetes Management